PALI
Palisade Bio, Inc. (NASDAQ)
Healthcare — Biotechnology
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
Price History
Fundamentals
| Market Cap | $342.35M |
| P/E Ratio (TTM) | 16.42 |
| Forward P/E | -6.90 |
| EPS (TTM) | $0.12 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -36.40% |
| Debt/Equity | - |
| Recommendation | Strong Buy 1.3 |
| Analyst Target | $10.50 |
| Analysts | 8 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 60.6 |
| Beta | 1.53 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $2.86 |
| 52-Week Low | $0.53 |
| 50-Day Avg | $1.94 |
| 200-Day Avg | $1.83 |
| Avg Volume | $3.53M |
| Volume | $3.85M |
Performance Analysis
BULLISHPALI shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:25 UTC
Back to Screener Export Report